Jonas Salk : medical innovator and polio vaccine developer
(Book)

Book Cover
Average Rating
Published
Minneapolis, MN : ABDO Publishing Company, [2014].
Physical Description
112 pages : illustrations (some color), portraits ; 24 cm.
Status

Summary

Loading Description...

Also in this Series

Checking series information...

Copies

LocationCall NumberStatus
Fremont Co. - Lander - Juvenile CollectionJB SALKOn Shelf

More Like This

Loading more titles like this title...

More Details

Published
Minneapolis, MN : ABDO Publishing Company, [2014].
Format
Book
Language
English
Accelerated Reader
MG
Level 7.2, 3 Points
Lexile Measure
960

Notes

Bibliography
Includes bibliographical references (pages 104-109) and index.
Summary
Examines the life of the American physician who developed the first polio vaccine.
Reading Level
12-19.
Reading Level
Grade: 6-12.
Reading Level
960 L,Lexile

Reviews from GoodReads

Loading GoodReads Reviews.

Citations

APA Citation, 7th Edition (style guide)

Llanas, S. G., & Wilson, D. J. (. o. h. (2014). Jonas Salk: medical innovator and polio vaccine developer . ABDO Publishing Company.

Chicago / Turabian - Author Date Citation, 17th Edition (style guide)

Llanas, Sheila Griffin, 1958- and Daniel J. (Professor of history) Wilson. 2014. Jonas Salk: Medical Innovator and Polio Vaccine Developer. ABDO Publishing Company.

Chicago / Turabian - Humanities (Notes and Bibliography) Citation, 17th Edition (style guide)

Llanas, Sheila Griffin, 1958- and Daniel J. (Professor of history) Wilson. Jonas Salk: Medical Innovator and Polio Vaccine Developer ABDO Publishing Company, 2014.

MLA Citation, 9th Edition (style guide)

Llanas, Sheila Griffin, and Daniel J. (Professor of history) Wilson. Jonas Salk: Medical Innovator and Polio Vaccine Developer ABDO Publishing Company, 2014.

Note! Citations contain only title, author, edition, publisher, and year published. Citations should be used as a guideline and should be double checked for accuracy. Citation formats are based on standards as of August 2021.